An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum]
Citrome L, Graham C, Simmons A, et al. Neuropsychiatr Dis Treat. 2021;17:2885–2904. The authors have advised there is an error in Figure 1C on page 2894. The key “OLZ/SAM” should read “Olanzapine + samidorphan 10 mg” and “Olanzapine&rdq...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2f956761b90540fb83ae4e6a7146f4e3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:2f956761b90540fb83ae4e6a7146f4e3 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:2f956761b90540fb83ae4e6a7146f4e32021-12-02T19:19:52ZAn Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum]1178-2021https://doaj.org/article/2f956761b90540fb83ae4e6a7146f4e32021-10-01T00:00:00Zhttps://www.dovepress.com/corrigendum-an-evidence-based-review-of-olzsam-for-treatment-of-adults-peer-reviewed-fulltext-article-NDThttps://doaj.org/toc/1178-2021Citrome L, Graham C, Simmons A, et al. Neuropsychiatr Dis Treat. 2021;17:2885–2904. The authors have advised there is an error in Figure 1C on page 2894. The key “OLZ/SAM” should read “Olanzapine + samidorphan 10 mg” and “Olanzapine” should read “Olanzapine + placebo”. Figure 1 legend, the text “Panel (C) In ALK3831-302, antipsychotic efficacy, as measured by the change from baseline in the PANSS total score at week 12 in the combined OLZ/SAM groups (OLZ/SAM 5/10 mg, 10/10 mg, and 20/10 mg) versus olanzapine was the primary endpoint; only the olanzapine + placebo and olanzapine + samidorphan 10-mg groups are presented here to allow cross-study comparisons” should read “Panel (C) In ALK3831-302, antipsychotic efficacy, as measured by the change from baseline in the PANSS total score at week 12, was the primary endpoint comparing the combined olanzapine + samidorphan groups versus the olanzapine + placebo group; to allow cross-study comparisons, only the olanzapine + samidorphan 10-mg and the olanzapine + placebo groups are presented here”. Read the original articleCitrome LGraham CSimmons AJiang YTodtenkopf MSSilverman BDiPetrillo LCummings HSun LMcDonnell DDove Medical Pressarticleantipsychotic agentsclinical efficacyolanzapineopioid antagonistssafetyweight gainNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 17, Pp 3135-3136 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
antipsychotic agents clinical efficacy olanzapine opioid antagonists safety weight gain Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
antipsychotic agents clinical efficacy olanzapine opioid antagonists safety weight gain Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Citrome L Graham C Simmons A Jiang Y Todtenkopf MS Silverman B DiPetrillo L Cummings H Sun L McDonnell D An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum] |
| description |
Citrome L, Graham C, Simmons A, et al. Neuropsychiatr Dis Treat. 2021;17:2885–2904.
The authors have advised there is an error in Figure 1C on page 2894. The key “OLZ/SAM” should read “Olanzapine + samidorphan 10 mg” and “Olanzapine” should read “Olanzapine + placebo”.
Figure 1 legend, the text “Panel (C) In ALK3831-302, antipsychotic efficacy, as measured by the change from baseline in the PANSS total score at week 12 in the combined OLZ/SAM groups (OLZ/SAM 5/10 mg, 10/10 mg, and 20/10 mg) versus olanzapine was the primary endpoint; only the olanzapine + placebo and olanzapine + samidorphan 10-mg groups are presented here to allow cross-study comparisons” should read “Panel (C) In ALK3831-302, antipsychotic efficacy, as measured by the change from baseline in the PANSS total score at week 12, was the primary endpoint comparing the combined olanzapine + samidorphan groups versus the olanzapine + placebo group; to allow cross-study comparisons, only the olanzapine + samidorphan 10-mg and the olanzapine + placebo groups are presented here”.
Read the original article |
| format |
article |
| author |
Citrome L Graham C Simmons A Jiang Y Todtenkopf MS Silverman B DiPetrillo L Cummings H Sun L McDonnell D |
| author_facet |
Citrome L Graham C Simmons A Jiang Y Todtenkopf MS Silverman B DiPetrillo L Cummings H Sun L McDonnell D |
| author_sort |
Citrome L |
| title |
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum] |
| title_short |
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum] |
| title_full |
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum] |
| title_fullStr |
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum] |
| title_full_unstemmed |
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum] |
| title_sort |
evidence-based review of olz/sam for treatment of adults with schizophrenia or bipolar i disorder [corrigendum] |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/2f956761b90540fb83ae4e6a7146f4e3 |
| work_keys_str_mv |
AT citromel anevidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT grahamc anevidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT simmonsa anevidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT jiangy anevidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT todtenkopfms anevidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT silvermanb anevidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT dipetrillol anevidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT cummingsh anevidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT sunl anevidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT mcdonnelld anevidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT citromel evidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT grahamc evidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT simmonsa evidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT jiangy evidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT todtenkopfms evidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT silvermanb evidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT dipetrillol evidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT cummingsh evidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT sunl evidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum AT mcdonnelld evidencebasedreviewofolzsamfortreatmentofadultswithschizophreniaorbipolaridisordercorrigendum |
| _version_ |
1718376844958367744 |